1
Clinical Trials associated with Anti-GD2 CART(Zhujiang Hospital)Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma
Patients with refractory and/or recurrent neuroblastoma have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. The investigators are attempt to treat this disease using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (CAR) targeting GD2 (4SCAR-GD2). The 4SCAR-GD2-modified T cells can recognize and kill neuroblastoma through the recognition of GD2, a surface protein expressed at high levels on neuroblastoma but not on normal tissues. This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and/or recurrent neuroblastoma.
100 Clinical Results associated with Anti-GD2 CART(Zhujiang Hospital)
100 Translational Medicine associated with Anti-GD2 CART(Zhujiang Hospital)
100 Patents (Medical) associated with Anti-GD2 CART(Zhujiang Hospital)
100 Deals associated with Anti-GD2 CART(Zhujiang Hospital)